View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, July 7 (HealthDay News) -- Cephalosporin susceptibility among Neisseria gonorrhoeae (N. gonorrhoeae) isolates appears to be declining; however, cephalosporins remain an effective treatment for gonorrhea, according to a report in the July 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
The CDC evaluated trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000 to 2010 with data from the Gonococcal Isolate Surveillance Project.
The data revealed that the percentage of isolates with elevated minimum inhibitory concentrations to cephalosporins increased from 0.2 percent in 2000 to 1.4 percent in 2010 for cefixime, and from 0.1 percent in 2000 to 0.3 percent in 2010 for ceftriaxone. The authors note that cephalosporins remain an effective treatment option for gonococcal infections.
"Health care providers should use ceftriaxone and azithromycin for treatment of gonorrhea, remain vigilant for gonorrhea cephalosporin treatment failures, and report treatment failures to their local or state health departments," the authors write.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top